Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy.

Intern Med · 2023 · PMC10037016 · PMID 35871587

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A prognostic analysis of the number of courses of azacitidine in the 0-point group showed a trend toward a longer OS for those with more than 14 courses of azacitidine than in those with fewer than 14 courses, but the difference was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.